YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$4.19 USD
-0.34 (-7.51%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $4.27 +0.08 (1.91%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
YMAB 4.19 -0.34(-7.51%)
Will YMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
Other News for YMAB
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
JonesTrading Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)